keyword
MENU ▼
Read by QxMD icon Read
search

memantine randomised controlled trial

keyword
https://www.readbyqxmd.com/read/29732913/augmentation-strategies-for-clozapine-refractory-schizophrenia-a-systematic-review-and-meta-analysis
#1
Dan J Siskind, Michael Lee, Arul Ravindran, Qichen Zhang, Evelyn Ma, Balaji Motamarri, Steve Kisely
BACKGROUND: Although clozapine is the most effective medication for treatment refractory schizophrenia, only 40% of people will meet response criteria. We therefore undertook a systematic review and meta-analysis of global literature on clozapine augmentation strategies. METHODS: We systematically reviewed PubMed, PsycInfo, Embase, Cochrane Database, Chinese Biomedical Literature Service System and China Knowledge Resource Integrated Database for randomised control trials of augmentation strategies for clozapine resistant schizophrenia...
May 1, 2018: Australian and New Zealand Journal of Psychiatry
https://www.readbyqxmd.com/read/29549516/effect-of-the-glutamate-nmda-receptor-antagonist-memantine-as-adjunctive-treatment-in-borderline-personality-disorder-an-exploratory-randomised-double-blind-placebo-controlled-trial
#2
Jayashri Kulkarni, Natalie Thomas, Abdul-Rahman Hudaib, Emorfia Gavrilidis, Jasmin Grigg, Raelene Tan, Jacinta Cheng, Amelia Arnold, Caroline Gurvich
BACKGROUND: Borderline personality disorder (BPD) is a complex, severe and highly stigmatised psychiatric illness. Several lines of evidence highlight the causal link between chronic stress, glucocorticoid response to stress and glutamatergic overactivity as a key event in the pathophysiology of BPD. Therefore, molecular mechanisms capable of regulating glutamate excitotoxicity represent novel and potentially promising treatment targets. Memantine-HCl is a voltage-dependent N-methyl-D-aspartate (NMDA) receptor 'channel blocker' that selectively blocks pathological glutamate overactivity...
February 2018: CNS Drugs
https://www.readbyqxmd.com/read/29239495/comparisons-between-traditional-medicines-and-pharmacotherapies-for-alzheimer-disease-a-systematic-review-and-meta-analysis-of-cognitive-outcomes
#3
REVIEW
Brian H May, Mei Feng, Anna J Hyde, Helmut Hügel, Su-Yueh Chang, Lin Dong, Xinfeng Guo, Anthony L Zhang, Chuanjian Lu, Charlie C Xue
OBJECTIVES: To evaluate the clinical evidence for traditional medicines (TMs) used in East Asia on measures of cognition in Alzheimer disease, determine the effect sizes at different time points for the TMs and pharmacotherapies, and assess the tolerability of the TMs. METHODS: We searched 12 databases in English, Chinese, and Japanese for eligible randomised controlled trials that compared orally administered TMs with pharmacotherapy and reported cognitive outcomes...
March 2018: International Journal of Geriatric Psychiatry
https://www.readbyqxmd.com/read/28122126/neuroprotection-for-treatment-of-glaucoma-in-adults
#4
REVIEW
Dayse F Sena, Kristina Lindsley
BACKGROUND: Glaucoma is a heterogeneous group of conditions involving progressive damage to the optic nerve, deterioration of retinal ganglion cells, and ultimately visual field loss. It is a leading cause of blindness worldwide. Open angle glaucoma (OAG), the most common form of glaucoma, is a chronic condition that may or may not present with increased intraocular pressure (IOP). Neuroprotection for glaucoma refers to any intervention intended to prevent optic nerve damage or cell death...
January 25, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28103749/clinical-practice-with-anti-dementia-drugs-a-revised-third-consensus-statement-from-the-british-association-for-psychopharmacology
#5
REVIEW
John T O'Brien, Clive Holmes, Matthew Jones, Roy Jones, Gill Livingston, Ian McKeith, Peter Mittler, Peter Passmore, Craig Ritchie, Louise Robinson, Elizabeth L Sampson, John-Paul Taylor, Alan Thomas, Alistair Burns
The British Association for Psychopharmacology coordinated a meeting of experts to review and revise its previous 2011 guidelines for clinical practice with anti-dementia drugs. As before, levels of evidence were rated using accepted standards which were then translated into grades of recommendation A-D, with A having the strongest evidence base (from randomised controlled trials) and D the weakest (case studies or expert opinion). Current clinical diagnostic criteria for dementia have sufficient accuracy to be applied in clinical practice (B) and both structural (computed tomography and magnetic resonance imaging) and functional (positron emission tomography and single photon emission computerised tomography) brain imaging can improve diagnostic accuracy in particular situations (B)...
February 2017: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/28072907/symptomatic-treatments-for-amyotrophic-lateral-sclerosis-motor-neuron-disease
#6
REVIEW
Louisa Ng, Fary Khan, Carolyn A Young, Mary Galea
BACKGROUND: Motor neuron disease (MND), which is also known as amyotrophic lateral sclerosis (ALS), causes a wide range of symptoms but the evidence base for the effectiveness of the symptomatic treatment therapies is limited. OBJECTIVES: To summarise the evidence from Cochrane Systematic Reviews of all symptomatic treatments for MND. METHODS: We searched the Cochrane Database of Systematic Reviews (CDSR) on 15 November 2016 for systematic reviews of symptomatic treatments for MND...
January 10, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/27739182/cost-effectiveness-of-donepezil-and-memantine-in-moderate-to-severe-alzheimer-s-disease-the-domino-ad-trial
#7
Martin Knapp, Derek King, Renée Romeo, Jessica Adams, Ashley Baldwin, Clive Ballard, Sube Banerjee, Robert Barber, Peter Bentham, Richard G Brown, Alistair Burns, Tom Dening, David Findlay, Clive Holmes, Tony Johnson, Robert Jones, Cornelius Katona, James Lindesay, Ajay Macharouthu, Ian McKeith, Rupert McShane, John T O'Brien, Patrick P J Phillips, Bart Sheehan, Robert Howard
OBJECTIVE: Most investigations of pharmacotherapy for treating Alzheimer's disease focus on patients with mild-to-moderate symptoms, with little evidence to guide clinical decisions when symptoms become severe. We examined whether continuing donepezil, or commencing memantine, is cost-effective for community-dwelling, moderate-to-severe Alzheimer's disease patients. METHODS: Cost-effectiveness analysis was based on a 52-week, multicentre, double-blind, placebo-controlled, factorial clinical trial...
December 2017: International Journal of Geriatric Psychiatry
https://www.readbyqxmd.com/read/27737513/pharmacologic-interventions-for-treating-phantom-limb-pain
#8
REVIEW
Maria Jenelyn M Alviar, Tom Hale, Monalisa Dungca
BACKGROUND: This is an updated version of the original Cochrane review published in Issue 12, 2011. Phantom limb pain (PLP) is pain that arises in the missing limb after amputation and can be severe, intractable, and disabling. Various medications have been studied in the treatment of phantom pain. There is currently uncertainty in the optimal pharmacologic management of PLP. OBJECTIVES: This review aimed to summarise the evidence of effectiveness of pharmacologic interventions in treating PLP...
October 14, 2016: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/27393698/withdrawal-of-antidementia-drugs-in-older-people-who-when-and-how
#9
REVIEW
Carole Parsons
The evidence base to guide withdrawal of antidementia medications in older people with dementia is limited; while some randomised controlled studies have considered discontinuation of cholinesterase inhibitors (ChEIs), no such studies examining discontinuation of the N-methyl-D-aspartate receptor antagonist memantine have been conducted to date. The purpose of this opinion article was to summarise the existing evidence on withdrawal of cholinesterase inhibitors and memantine, to highlight the key considerations for clinicians when making these prescribing decisions and to offer guidance as to when and how treatment might be discontinued...
August 2016: Drugs & Aging
https://www.readbyqxmd.com/read/27121704/interventions-to-delay-functional-decline-in-people-with-dementia-a-systematic-review-of-systematic-reviews
#10
REVIEW
Kate Laver, Suzanne Dyer, Craig Whitehead, Lindy Clemson, Maria Crotty
OBJECTIVE: To summarise existing systematic reviews that assess the effects of non-pharmacological, pharmacological and alternative therapies on activities of daily living (ADL) function in people with dementia. DESIGN: Overview of systematic reviews. METHODS: A systematic search in the Cochrane Database of Systematic Reviews, DARE, Medline, EMBASE and PsycInfo in April 2015. Systematic reviews of randomised controlled trials conducted in people with Alzheimer's disease or dementia measuring the impact on ADL function were included...
April 27, 2016: BMJ Open
https://www.readbyqxmd.com/read/26983548/glutamatergic-medication-in-the-treatment-of-obsessive-compulsive-disorder-ocd-and-autism-spectrum-disorder-asd-study-protocol-for-a-randomised-controlled-trial
#11
RANDOMIZED CONTROLLED TRIAL
Alexander Häge, Tobias Banaschewski, Jan K Buitelaar, Rick M Dijkhuizen, Barbara Franke, David J Lythgoe, Konstantin Mechler, Steven C R Williams, Ralf W Dittmann
BACKGROUND: Compulsivity is a cross-disorder trait underlying phenotypically distinct psychiatric disorders that emerge in childhood or adolescence. Despite the effectiveness of serotonergic compounds in the treatment of obsessive-compulsive disorder, treatment-resistant symptoms remaining in 40 to 60 % of patients present a pressing clinical problem. There are currently no medications that effectively treat the core impairments of autism spectrum disorder. There is an urgent need for the development of conceptually novel pharmacological strategies...
March 17, 2016: Trials
https://www.readbyqxmd.com/read/26515660/nursing-home-placement-in-the-donepezil-and-memantine-in-moderate-to-severe-alzheimer-s-disease-domino-ad-trial-secondary-and-post-hoc-analyses
#12
RANDOMIZED CONTROLLED TRIAL
Robert Howard, Rupert McShane, James Lindesay, Craig Ritchie, Ashley Baldwin, Robert Barber, Alistair Burns, Tom Dening, David Findlay, Clive Holmes, Robert Jones, Roy Jones, Ian McKeith, Ajay Macharouthu, John O'Brien, Bart Sheehan, Edmund Juszczak, Cornelius Katona, Robert Hills, Martin Knapp, Clive Ballard, Richard G Brown, Sube Banerjee, Jessica Adams, Tony Johnson, Peter Bentham, Patrick P J Phillips
BACKGROUND: Findings from observational studies have suggested a delay in nursing home placement with dementia drug treatment, but findings from a previous randomised trial of patients with mild-to-moderate Alzheimer's disease showed no effect. We investigated the effects of continuation or discontinuation of donepezil and starting of memantine on subsequent nursing home placement in patients with moderate-to-severe Alzheimer's disease. METHODS: In the randomised, double-blind, placebo-controlled Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial, community-living patients with moderate-to-severe Alzheimer's disease (who had been prescribed donepezil continuously for at least 3 months at a dose of 10 mg for at least the previous 6 weeks and had a score of between 5 and 13 on the Standardised Mini-Mental State Examination) were recruited from 15 secondary care memory centres in England and Scotland and randomly allocated to continue donepezil 10 mg per day without memantine, discontinue donepezil without memantine, discontinue donepezil and start memantine 20 mg per day, or continue donepezil 10 mg per day and start memantine 20 mg per day, for 52 weeks...
December 2015: Lancet Neurology
https://www.readbyqxmd.com/read/26513128/pharmacological-interventions-for-cognitive-decline-in-people-with-down-syndrome
#13
REVIEW
Nuala Livingstone, Jennifer Hanratty, Rupert McShane, Geraldine Macdonald
BACKGROUND: People with Down syndrome are vulnerable to developing dementia at an earlier age than the general population. Alzheimer's disease and cognitive decline in people with Down syndrome can place a significant burden on both the person with Down syndrome and their family and carers. Various pharmacological interventions, including donepezil, galantamine, memantine and rivastigmine, appear to have some effect in treating cognitive decline in people without Down syndrome, but their effectiveness for those with Down syndrome remains unclear...
October 29, 2015: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/26447539/interventions-for-fatigue-in-parkinson-s-disease
#14
REVIEW
Roy G Elbers, John Verhoef, Erwin Eh van Wegen, Henk W Berendse, Gert Kwakkel
BACKGROUND: Factors contributing to subjective fatigue in people with idiopathic Parkinson's disease (PD) are not well known. This makes it difficult to manage fatigue effectively in PD. OBJECTIVES: To evaluate the effects of pharmacological and non-pharmacological interventions, compared to an inactive control intervention, on subjective fatigue in people with PD. SEARCH METHODS: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library); MEDLINE (via PubMed); Ovid EMBASE; EBSCO CINAHL; Ovid PsycINFO; PEDro; and the WHO International Clinical Trials Registry Platform Search Portal up to April 2015...
October 8, 2015: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/26415966/ketamine-and-other-glutamate-receptor-modulators-for-depression-in-bipolar-disorder-in-adults
#15
REVIEW
Tayla L McCloud, Caroline Caddy, Janina Jochim, Jennifer M Rendell, Peter R Diamond, Claire Shuttleworth, Daniel Brett, Ben H Amit, Rupert McShane, Layla Hamadi, Keith Hawton, Andrea Cipriani
BACKGROUND: There is emerging evidence that glutamatergic system dysfunction might play an important role in the pathophysiology of bipolar depression. This review focuses on the use of glutamate receptor modulators for depression in bipolar disorder. OBJECTIVES: 1. To assess the effects of ketamine and other glutamate receptor modulators in alleviating the acute symptoms of depression in people with bipolar disorder.2. To review the acceptability of ketamine and other glutamate receptor modulators in people with bipolar disorder who are experiencing acute depression symptoms...
September 29, 2015: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/26395901/ketamine-and-other-glutamate-receptor-modulators-for-depression-in-adults
#16
REVIEW
Caroline Caddy, Ben H Amit, Tayla L McCloud, Jennifer M Rendell, Toshi A Furukawa, Rupert McShane, Keith Hawton, Andrea Cipriani
BACKGROUND: Considering the ample evidence of involvement of the glutamate system in the pathophysiology of depression, pre-clinical and clinical studies have been conducted to assess the antidepressant efficacy of glutamate inhibition, and glutamate receptor modulators in particular. This review focuses on the use of glutamate receptor modulators in unipolar depression. OBJECTIVES: To assess the effects - and review the acceptability - of ketamine and other glutamate receptor modulators in comparison to placebo (or saline placebo), other pharmacologically active agents, or electroconvulsive therapy (ECT) in alleviating the acute symptoms of depression in people with unipolar major depressive disorder...
September 23, 2015: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/26121895/effects-of-memantine-on-pain-in-patients-with-complex-regional-pain-syndrome-a-retrospective-study
#17
Mohammad-Hazem Ahmad-Sabry, Gholamreza Shareghi
INTRODUCTION: Memantine was discovered in 1968 and is used as a treatment for Alzheimer's disease. We evaluated the use of memantine to treat complex regional pain syndrome in this retrospective study. PATIENTS AND METHODS: 56 patients with CRPS, who were treated with trial of memantine for at least two months with 40mg QHS from 2007 until 2009. RESULTS: 34 females and 22 male patients. Age-46.0 +/- 9.7 years. Number of years with CRPS-9.24 ± 5...
February 2015: Middle East Journal of Anesthesiology
https://www.readbyqxmd.com/read/25519950/interventions-for-preventing-and-ameliorating-cognitive-deficits-in-adults-treated-with-cranial-irradiation
#18
REVIEW
Julia Day, Karolis Zienius, Karin Gehring, David Grosshans, Martin Taphoorn, Robin Grant, Jing Li, Paul D Brown
BACKGROUND: Cognitive deficits are common in people who have received cranial irradiation and have a serious impact on daily functioning and quality of life. The benefit of pharmacological and non-pharmacological treatment of cognitive deficits in this population is unclear. OBJECTIVES: To assess the effectiveness of interventions for preventing or ameliorating cognitive deficits in adult patients treated with cranial irradiation. SEARCH METHODS: In August 2014...
December 18, 2014: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/25218600/efficacy-of-memantine-in-the-treatment-of-fibromyalgia-a-double-blind-randomised-controlled-trial-with-6-month-follow-up
#19
RANDOMIZED CONTROLLED TRIAL
Bárbara Olivan-Blázquez, Paola Herrera-Mercadal, Marta Puebla-Guedea, Mari-Cruz Pérez-Yus, Eva Andrés, Nicolas Fayed, Yolanda López-Del-Hoyo, Rosa Magallon, Miquel Roca, Javier Garcia-Campayo
Fibromyalgia (FM) is a prevalent and disabling chronic disease. Recent studies have found elevated levels of glutamate in several brain regions, leading to hypotheses about the usefulness of glutamate-blocking drugs such as memantine in the treatment of FM. The aim of this study was to evaluate the efficacy of memantine in the treatment of pain and other clinical variables (global function, clinical impression, depression, anxiety, quality of life) in FM patients. A double-blind, parallel randomised controlled trial was developed...
December 2014: Pain
https://www.readbyqxmd.com/read/24993765/treatment-effect-of-memantine-on-survival-in-dementia-with-lewy-bodies-and-parkinson-s-disease-with-dementia-a-prospective-study
#20
RANDOMIZED CONTROLLED TRIAL
Kajsa Stubendorff, Victoria Larsson, Clive Ballard, Lennart Minthon, Dag Aarsland, Elisabet Londos
OBJECTIVE: To investigate the effect on survival of treatment with memantine in patients with dementia with Lewy bodies (DLB) and Parkinson's disease with dementia (PDD). METHODS: 75 patients with DLB and PDD were included in a prospective double-blinded randomised placebo-controlled trial (RCT) of memantine, of whom long-term follow-up was available for 42. Treatment response was recorded 24 weeks from baseline and measured by Clinical Global Impression of Change (CGIC)...
2014: BMJ Open
keyword
keyword
81573
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"